var data={"title":"Nevirapine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nevirapine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6645?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">see &quot;Nevirapine: Drug information&quot;</a> and <a href=\"topic.htm?path=nevirapine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nevirapine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709170\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe, life-threatening, and, in some cases, fatal hepatotoxicity, particularly in the first 18 weeks, has been reported in patients treated with nevirapine. In some cases, patients presented with nonspecific prodromal signs or symptoms of hepatitis and progressed to hepatic failure. These events are often associated with rash. Women and patients with higher CD4<sup>+</sup> cell counts at initiation of therapy are at increased risk. Women with CD4<sup>+</sup> cell counts higher than 250 cells/mm<sup>3</sup>, including pregnant women receiving nevirapine in combination with other antiretrovirals for treatment of HIV-1 infection, are at the greatest risk. However, hepatotoxicity associated with nevirapine use can occur in both genders, at all CD4<sup>+</sup> cell counts, and at any time during treatment. Hepatic failure has also been reported in patients without HIV taking nevirapine for postexposure prophylaxis. Use of nevirapine for occupational and nonoccupational postexposure prophylaxis is contraindicated. Patients with signs or symptoms of hepatitis, or with increased transaminases combined with rash or other systemic symptoms, must discontinue nevirapine and seek medical evaluation immediately.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Skin reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe, life-threatening skin reactions, including fatal cases, have occurred in patients treated with nevirapine. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction. Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue nevirapine and seek medical evaluation immediately. Check transaminase levels immediately for all patients who develop a rash in the first 18 weeks of treatment. The 14-day lead-in period with nevirapine 200 mg immediate release daily dosing has been observed to decrease the incidence of rash and must be followed.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Monitoring for hepatotoxicity and skin reactions</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients must be monitored intensively during the first 18 weeks of therapy with nevirapine to detect potentially life-threatening hepatotoxicity or skin reactions. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these reactions. Do not restart nevirapine following clinical hepatitis, transaminase elevations combined with rash or other systemic symptoms, or following severe skin rash or hypersensitivity reactions. In some cases, hepatic injury has progressed despite discontinuation of treatment.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200898\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Viramune;</li>\n      <li>Viramune XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200899\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Nevirapine XR;</li>\n      <li>Auro-Nevirapine;</li>\n      <li>Mylan-Nevirapine;</li>\n      <li>PMS-Nevirapine;</li>\n      <li>Teva-Nevirapine;</li>\n      <li>Viramune;</li>\n      <li>Viramune XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054342\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">HIV Agents (Anti-HIV Agents)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443899\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection, treatment:</b> Use in combination with other antiretroviral agents: <b>Note:</b> If patient experiences a nonsevere rash (in the absence of transaminase elevations) during the first 14 days of therapy, do not increase dose until rash has resolved. If rash continues beyond 28 days, use an alternative regimen. Discontinue nevirapine if severe rash, rash with constitutional symptoms, or rash with elevated hepatic transaminases occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &le;14 days: AIDS<i>info</i> pediatric guidelines: Limited data available; dose not established: Based on pharmacokinetic modeling, the following investigational doses (without lead-in once-daily dosing) are being studied (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA 34 to &lt;37 weeks: Oral: <i>Immediate release:</i> 4 mg/kg/dose twice daily for the first week, then increase to 6 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;37 weeks: Oral: <i>Immediate release:</i> 6 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &ge;15 days: Oral: <i>Immediate release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Initial: 150 mg/m<sup>2</sup>/dose (maximum: 200 mg/dose) once daily for the first 14 days of therapy; increase to 150 mg/m<sup>2</sup>/dose twice daily if no rash or other adverse effects occur; maximum dose: 200 mg/dose every 12 hours. If nevirapine therapy is interrupted for &gt;7 days, restart at the initial recommended dose (ie, once daily for the first 14 days) before increasing to twice daily dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AIDS<i>info</i> pediatric guidelines: Limited data available; dose not established: Gestational age &ge;34 weeks: 6 mg/kg/dose twice daily (without lead-in once-daily dosing); investigational dose based on pharmacokinetic modeling (HHS [pediatric] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 perinatal transmission, prevention</b> [HHS (perinatal) 2017]; <b>Note:</b> A combination prophylaxis regimen is recommended for neonates at higher risk of HIV acquisition, including neonates born to HIV-infected mothers who have not received antepartum or intrapartum antiretroviral (ARV) therapy, have received only intrapartum ARV therapy, or received antepartum ARV therapy but with suboptimal viral suppression. Prevention therapy should begin as soon as possible after birth (ideally within 6 to 12 hours after delivery). If neonate is diagnosed as HIV positive, discontinue prevention (prophylaxis) dosing and begin a treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Two-drug combination (with zidovudine): Newborn: Oral: <i>Immediate release:</i> Administer <b>three</b> doses of nevirapine within the first week of life; administer the first dose as soon as possible after birth, but within 48 hours (birth to 48 hours); administer the second dose 48 hours after the first dose; administer the third dose 96 hours after the second dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Birthweight 1.5 to 2 kg: 8 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Birthweight &gt;2 kg: 12 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Three-drug combination (with lamivudine and zidovudine): Limited data available: <b>Note:</b> Optimal duration unknown; some experts recommend a 6-week course, while others recommend discontinuation after 2 weeks if HIV nucleic acid amplification test is negative.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;34 to &lt;37 weeks: Oral: <i>Immediate release</i>: 4 mg/kg/dose twice daily for 1 week; then at 1 week of age, increase dose to 6 mg/kg/dose twice daily and continue for 5 weeks; total duration of nevirapine therapy: 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;37 weeks: Oral: <i>Immediate release</i>: 6 mg/kg/dose twice daily for 6 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054335\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">see &quot;Nevirapine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 perinatal transmission, prevention:</b> [HHS (perinatal) 2017]; <b>Note:</b> A combination prophylaxis regimen is recommended for neonates at higher risk of HIV acquisition, including neonates born to HIV-infected mothers who have not received antepartum or intrapartum antiretroviral (ARV) therapy, have received only intrapartum ARV therapy, or received antepartum ARV therapy but with suboptimal viral suppression. Prevention therapy should begin as soon as possible after birth (ideally within 6 to 12 hours after delivery). If neonate is diagnosed as HIV positive, discontinue prevention (prophylaxis) dosing and begin a treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Three-drug combination (with lamivudine and zidovudine): Limited data available: Infants PNA &le;6 weeks (GA &ge;34 weeks): Oral: <i>Immediate release</i>: 6 mg/kg/dose twice daily; total duration: 2 to 6 weeks; optimal duration unknown; some experts recommend a 6-week course, while others recommend discontinuation after 2 weeks if HIV nucleic acid amplification test is negative</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 infection, treatment:</b> Use in combination with other antiretroviral agents: <b>Note:</b> If patient experiences a nonsevere rash (in the absence of transaminase elevations) during the first 14 days of therapy, do not increase dose until rash has resolved. If rash continues beyond 28 days, use an alternative regimen. Discontinue nevirapine if severe rash, rash with constitutional symptoms, or rash with elevated hepatic transaminases occurs. If nevirapine therapy is interrupted for &gt;7 days (adults/adolescents) or &gt;14 days (infants/children), restart at the initial recommended dose (ie, once daily for the first 14 days) before increasing to twice daily dosing (HHS [pediatric] 2017). Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Immediate release:</i> AIDS<i>info</i> guidelines (HHS [pediatric] 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;8 years: Initial (lead-in dosing): 200 mg/m<sup>2</sup>/dose (maximum dose: 200 mg/dose) once daily for the first 14 days of therapy; increase to 200 mg/m<sup>2</sup>/dose (maximum dose: 200 mg/dose) twice daily if no rash or other adverse effects occur; maximum dose: 200 mg twice daily. <b>Note:</b> Some experts recommend initiating therapy in infants and children &le;2 years of age at twice-daily dosing without a lead-in titration.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;8 years: Initial (lead-in dosing): 120 to 150 mg/m<sup>2</sup>/dose (maximum dose: 200 mg/dose) once daily for the first 14 days of therapy; increase to 120 to 150 mg/m<sup>2</sup>/dose (maximum dose: 200 mg/dose) twice daily if no rash or other adverse effects occur. <b>Note:</b> In a growing child, do not decrease the mg dose when the child reaches 8 years; leave the mg dose the same to achieve the appropriate mg/m<sup>2</sup>/dose as the child grows larger (as long as there are no adverse effects)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Initial: 200 mg once daily for the first 14 days; increase to 200 mg every 12 hours if no rash or other adverse effects occur; if patient able to swallow tablets whole, may convert maintenance dose to the extended release formulation (400 mg once daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended release:</i> Children &ge;6 years and Adolescents (must be able to swallow tablets whole): <b>Note:</b> For patients already on full-dose nevirapine, may initiate extended release preparation without lead-in dosing. If initiating nevirapine therapy, begin with the age-appropriate once daily dose of the immediate release formulation for the first 14 days of therapy; at 14 days, if no rash or other adverse effects have occurred, increase dose to the age-appropriate dose administered once daily for the extended release formulation. Extended release tablets should not be divided to achieve daily dose. Body-surface area directed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA 0.58 to 0.83 m<sup>2</sup>: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA 0.84 to 1.16 m<sup>2</sup>: 300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA &ge;1.17 m<sup>2</sup>: 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>HIV-1 infection, treatment:</b> Use in combination with other antiretroviral agents; <b>Note:</b> Therapy in antiretroviral-naive patients should not be initiated in patients with elevated CD4<sup>+</sup> cell counts unless the benefit of therapy outweighs the risk of serious hepatotoxicity (adult/postpubertal females: CD4<sup>+</sup> cell counts &gt;250 cells/mm<sup>3</sup>; adult males: CD4<sup>+</sup> cell counts &gt;400 cells/mm<sup>3</sup>).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: Immediate release: Oral: 200 mg once daily for the first 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Oral: 200 mg twice daily if no rash or other adverse effects occur during initial dosing period</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Oral: 400 mg once daily; <b>Note:</b> Maintenance therapy using the extended release tablet must follow a 14-day initial dosing period (lead-in) using the immediate release formulation, unless the patient is already maintained on a nevirapine immediate release regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">N<b>ote:</b> If patient experiences a nonsevere rash (in the absence of transaminase elevations) during the 14-day lead-in period, dose should not be increased until the rash has resolved. A lead-in period must always be done with immediate release formulation and regimen should not exceed 28 days; alternative treatment should be considered at that point. If a rash occurs within the first 18 weeks of therapy, immediately check serum transaminases. Discontinue if severe rash, rash with constitutional symptoms, or rash with elevated hepatic transaminases is noted. If therapy with any formulation is interrupted for &gt;7 days, restart with initial dose of immediate release formulation for 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;20 mL/minute: No dosage adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;20 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Adults: An additional 200 mg dose of immediate release tablet is recommended following dialysis. <b>Note:</b> Nevirapine metabolites may accumulate in patients on dialysis (clinical significance is unknown)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution; monitor for symptoms of drug-induced toxicity (increased trough concentrations have been observed in some patients with hepatic fibrosis or cirrhosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe impairment (Child-Pugh class B or C): Use is contraindicated; permanently discontinue if symptomatic hepatic events occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200874\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Viramune: 50 mg/5 mL (240 mL) [contains methylparaben, polysorbate 80, propylparaben, sorbitol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (240 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Viramune: 200 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Viramune XR: 100 mg, 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200858\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874746\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020636s048,020933s038lbl.pdf#page=19&amp;token=gHtkYWRdJ9y3+WBzgqG1d0VIA4IQE+Jy5dwvNca7tYj1o6sFFTVSdCXpv4f+KumsHXESPCOC57veHzc8VOqXZ7hBgofzOJI4mgdOCExOevFYbDujHi28IJeFKaNgZBkG&amp;TOPIC_ID=12961\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020636s048,020933s038lbl.pdf#page=19</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054346\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: May be administered with water, milk, or soda, with or without meals; may be administered with an antacid or didanosine. Shake suspension gently prior to administration; the use of an oral dosing syringe is recommended, especially if the dose is &lt;5 mL; if using a dosing cup, after administration, rinse cup with water and also administer rinse.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: May be administered with or without food; swallow tablet whole; do not chew, crush, or divide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132873\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3099313\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursion permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054345\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of HIV-1 infection in combination with other antiretroviral agents (Immediate release: FDA approved in ages &ge;15 days and adults; Extended release: FDA approved in ages &ge;6 years and adults). <b>Note:</b> HIV regimens consisting of three antiretroviral agents are strongly recommended. Do not start nevirapine therapy in women with CD4+ counts &gt;250 cells/mm<sup>3</sup> or in men with CD4+ counts &gt;400 cells/mm<sup>3</sup> unless benefit of therapy outweighs the risk. Nevirapine has also been used as chemoprophylaxis in newborns to prevent perinatal HIV transmission.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200943\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nevirapine may be confused with nelfinavir </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Viramune, Viramune XR may be confused with Viracept, Viramune (herbal product)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200941\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Potentially life-threatening nevirapine-associated adverse effects may present with the following symptoms: Abrupt onset of flu-like symptoms, abdominal pain, jaundice, or fever with or without rash; may progress to hepatic failure with encephalopathy. Skin rash is present in approximately 50% of cases.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased amylase, increased LDL cholesterol, increased serum cholesterol</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic disease (symptomatic, including hepatitis and hepatic failure: risk higher in ARV-na&iuml;ve women with CD4 counts &gt;250 cells/mm<sup>3</sup> and ARV-na&iuml;ve men with CD4 counts &gt;400 cells/mm<sup>3</sup>), increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, anemia, angioedema, aphthous stomatitis, bullous rash, cholestatic hepatitis, conjunctivitis, DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), eosinophilia, fulminant hepatitis, granulocytopenia, hepatic necrosis, hypersensitivity reaction, hypophosphatemia, immune reconstitution syndrome, jaundice, lipotrophy, lymphadenopathy, oral lesion, redistribution of body fat, renal insufficiency, rhabdomyolysis, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200880\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate to severe hepatic impairment (Child-Pugh class B or C); use in occupational or nonoccupational postexposure prophylaxis (PEP) regimens</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Clinically significant hypersensitivity to nevirapine or any component of the formulation; therapy rechallenge in patients with prior hypersensitivity reactions, severe rash, rash accompanied by constitutional symptoms, or clinical hepatitis due to nevirapine; severe hepatic dysfunction or AST or ALT &gt;5 times ULN (pretreatment or during prior use of nevirapine); hereditary conditions of galactose intolerance (eg, galactosemia, Lapp lactase deficiency, glucose-galactose malabsorption); concomitant use of herbal products containing St John's wort</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200862\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fat redistribution: May cause redistribution/accumulation of fat (eg, central obesity, buffalo hump, peripheral wasting, facial wasting, breast enlargement, cushingoid appearance).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: Severe, life-threatening hepatotoxicity, sometimes fatal, may occur; in some cases, patients have presented with non-specific prodromal signs/symptoms of hepatitis that have progressed to hepatic failure. May be associated with rash. Risk is greatest in the first 6 weeks of therapy. Female gender and higher CD4<sup>+</sup> cell counts at treatment initiation increase risk of hepatotoxicity; women with CD4<sup>+</sup> cell counts &gt;250 cells/mm<sup>3</sup>, including pregnant women, are at greatest risk. Hepatic failure has also been reported in patients without HIV taking nevirapine for post-exposure prophylaxis (PEP); use is contraindicated for occupational or non-occupational PEP. Monitor patients intensively during the first 18 weeks of therapy. Discontinue treatment in patients with signs/symptoms of hepatitis or with increased transaminases combined with rash or other systemic symptoms; in some cases, hepatic injury has progressed despite discontinuation. Do not restart nevirapine following clinical hepatitis or transaminase elevations combined with rash or other systemic symptoms.</b> Patients with a history of chronic hepatitis (B or C) or increased baseline transaminase levels may be at increased risk of later symptomatic events (&ge;6 weeks after treatment initiation) and asymptomatic increases in AST or ALT.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome, resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rhabdomyolysis: Has been observed in conjunction with skin and/or hepatic adverse events. Discontinuation of therapy is warranted with evidence of severe skin or liver toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: <b>[US Boxed Warning]:</b> <b>Severe, life-threatening skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, hypersensitivity reactions with rash and organ dysfunction), including fatal cases, have occurred. The 14-day lead-in dosing period must be followed and has been shown to decrease incidence of rash. The greatest risk of these reactions is within the initial 6 weeks of treatment; intensive monitoring is required during the initial 18 weeks of therapy to detect potentially life-threatening dermatologic and hypersensitivity reactions. Discontinue use in patients who develop signs/symptoms of severe skin reactions or hypersensitivity reactions; do not restart nevirapine in these patients. Immediately evaluate transaminase levels in all patients who develop rash in the first 18 weeks of treatment.</b> If mild to moderate rash without constitutional symptoms occurs during the 14-day lead-in period, do not increase dose until resolution of rash. If rash continues beyond 28 days, consider an alternative regimen. Coadministration of prednisone during the first 6 weeks of therapy increases incidence and severity of rash; concomitant prednisone is not recommended to prevent rash.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with preexisting dysfunction; monitor closely for drug-induced hepatotoxicity. Use is contraindicated in patients with moderate to severe impairment (Child-Pugh class B or C).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: When initiating therapy, a 14-day lead-in dose with the immediate release formulation should be used to decrease risk of skin reactions. If rash appears during the 14-day lead-in period, do not increase the dose or initiate the extended release formulation until the rash has resolved. An alternative regimen should be used if the lead-in dose period exceeds 28 days. Therapy in antiretroviral naive patients should not be initiated in patients with elevated CD4<sup>+</sup>-cell counts unless the benefit of therapy outweighs the risk of serious hepatotoxicity (adult/postpubertal females: CD4<sup>+</sup>-cell counts &gt;250 cells/mm<sup>3</sup>; adult males: CD4<sup>+</sup>-cell counts &gt;400 cells/mm<sup>3</sup>). If CD4<sup>+</sup>-cell counts increase above these thresholds as a result of nevirapine-containing therapy, therapy may be continued. After the lead-in period, patients may be switched to the extended-release formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Resistance: Due to rapid emergence of resistance, nevirapine should not be used as monotherapy or the only agent added to a failing regimen for the treatment of HIV. Resistance may occur with a single mutation and cross-resistance may be conferred to other non-nucleoside reverse transcriptase inhibitors (HHS [adult] 2016). When discontinuing an antiretroviral regimen containing nevirapine, take into account the long half-life of nevirapine. If other agents with shorter half-lives are stopped concurrently, low nevirapine plasma concentrations may persist for a week or longer and virus resistance may subsequently develop.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26018389\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The incidence of rash in pediatric patients is 21%. Granulocytopenia may occur; more common in neonates and young infants (2 weeks to &lt;3 months of age) compared to older children and adults; also more common in pediatric patients receiving concomitant zidovudine. Anemia may occur at an incidence of 7.3%; it has been reported more commonly in children in postmarketing reports; however, effects of concomitant medications cannot be separated out. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In perinatally HIV-exposed infants, the sensitivity of diagnostic virologic assays, particularly HIV RNA assays, may be affected by infant combination antiretroviral prophylactic therapy. Thus, a negative result of a diagnostic virologic assay should be repeated 2 to 4 weeks after cessation of neonatal combination antiretroviral prophylactic therapy (HHS [pediatric] 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200929\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> MRP2; <b>Induces</b> CYP2B6 (moderate), CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200867\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12961&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Artemether: Nevirapine may decrease the serum concentration of Artemether. Nevirapine may also increase or decrease serum concentrations of lumefantrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artesunate: Nevirapine may decrease serum concentrations of the active metabolite(s) of Artesunate. Nevirapine may increase the serum concentration of Artesunate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: May increase the serum concentration of Nevirapine. Nevirapine may decrease the serum concentration of Atazanavir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Nevirapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2B6 Substrates (High risk with Inducers): CYP2B6 Inducers (Moderate) may decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: Nevirapine may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of Nevirapine. Nevirapine may increase the serum concentration of Darunavir. Management: No action is required if darunavir/ritonavir is combined with nevirapine. The combination of darunavir/cobicistat and nevirapine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Nevirapine may decrease the serum concentration of Dolutegravir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May enhance the adverse/toxic effect of Nevirapine. Nevirapine may enhance the adverse/toxic effect of Efavirenz. Nevirapine may decrease the serum concentration of Efavirenz.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: Nevirapine may decrease the serum concentration of Elvitegravir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergonovine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Ergonovine. Specifically, this would be most likely with delavrdine, while other Non-Nucleoside Reverse Transcriptase Inhibitors may be more likely to decrease the concentration of Ergonovine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Systemic): Nevirapine may decrease the serum concentration of Estriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Topical): Nevirapine may decrease the serum concentration of Estriol (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Nevirapine may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Nevirapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Nevirapine may decrease serum concentrations of the active metabolite(s) of Fosamprenavir.  Management: Coadministration of nevirapine and fosamprenavir is not recommended without concurrent ritonavir.  However, when nevirapine and fosamprenavir/ritonavir (twice daily) are used in combination, no dose adjustment is required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Nevirapine may decrease the serum concentration of Indinavir.  Management: Increased indinavir doses may be needed when used with nevirapine; however, specific dosing guidelines have not been established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Nevirapine may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Nevirapine may decrease the serum concentration of Ketoconazole (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: Nevirapine may decrease the serum concentration of Lopinavir.  Management: Avoid once daily use of lopinavir/ritonavir with nevirapine.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for recommended dose increases in other patients.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone.  Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Nevirapine may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Nevirapine may decrease the serum concentration of Nelfinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Nevirapine may decrease the serum concentration of Progestins (Contraceptive).  Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifabutin: May decrease the serum concentration of Nevirapine. Nevirapine may decrease the serum concentration of Rifabutin. Nevirapine may increase the serum concentration of Rifabutin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Nevirapine. Management: Avoid whenever possible. When this combination is necessary, use immediate-release nevirapine (avoid extended-release nevirapine) at a dose of 200 mg twice daily with no lead-in (per adult/adolescent HIV guidelines).  Monitor nevirapine response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Nevirapine may decrease the serum concentration of Rivaroxaban. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Nevirapine may decrease the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: Nevirapine may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, St. Johns Wort may increase the metabolism of Reverse Transcriptase Inhibitors (Non-Nucleoside).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: CYP2B6 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside).  Management: Consider avoiding when possible. Use efavirenz with voriconazole only if voriconazole is dosed at 400 mg every 12 hours and efavirenz is dosed at 300 mg daily (adult doses) throughout therapy. Avoid Atripla (efavirenz/emtricitabine/tenofovir).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Nevirapine may diminish the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200884\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Nevirapine has a high level of transfer across the human placenta. No increased risk of overall birth defects following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may increase the risk of preterm delivery, although available information is conflicting possibly due to variability of maternal factors (disease severity; gestational age at initiation of therapy); however, maternal antiretroviral medication should not be withheld due to concerns of preterm birth. Information related to stillbirth, low birth weight, and small for gestational age infants is limited. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children who develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential mitochondrial dysfunction.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>[US Boxed Warning]: Severe, life-threatening hepatotoxicity, sometimes fatal, may occur; risk is greatest in the first 6 weeks of therapy. Female gender and higher CD4<sup>+</sup> cell counts at treatment initiation increase risk of hepatotoxicity; women with CD4<sup>+</sup> cell counts &gt;250 cells/mm<sup>3</sup>, including pregnant women, are at greatest risk, </b>although pregnancy itself does not appear to increase this risk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines do not recommend nevirapine as an initial NNRTI for use in antiretroviral-naive pregnant patients because of the potential for adverse events, complex dosing, and low barrier to resistance. Pharmacokinetics of the immediate-release formulation are not significantly altered during pregnancy; dose adjustment is not currently recommended (data not available for extended-release formulation). Females who become pregnant while on nevirapine therapy and are tolerating it well may continue. Frequent monitoring is recommended.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, ART is recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. When HIV is diagnosed during pregnancy in a female who has never received antiretroviral therapy, ART should begin as soon as possible after diagnosis. Females who become pregnant on a stable ART regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated. Monitoring during pregnancy is more frequent than in nonpregnant adults; ART should be continued postpartum for all females living with HIV.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054341\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The absolute CD4 cell count is currently recommended to monitor immune status in children of all ages; CD4 percentage can be used as an alternative in children &lt;5 years of age. This recommendation is based on the use of absolute CD4 cell counts in the current pediatric HIV infection stage classification and as thresholds for urgency of initiation of antiretroviral treatment (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Prior to initiation of therapy: Genotypic resistance testing, CD4 and viral load (every 3 to 4 months), CBC with differential, LFTs, BUN, creatinine, electrolytes, glucose, urinalysis (every 6 to 12 months), and assessment of readiness for adherence with medication regimen. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, urinalysis (at initiation), BUN, creatinine, albumin, total protein, lipid panel (at initiation), CD4, and viral load. After 1 to 2 weeks of therapy: Signs of medication toxicity and adherence. After 2 to 4 weeks of therapy: CBC with differential, viral load, signs of toxicity, and adherence; then every 3 to 4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, viral load, signs of medication toxicity, and adherence. Every 6 to 12 months: Lipid panel and urinalysis. CD4 monitoring frequency may be decreased to every 6 to 12 months in children who are adherent to therapy if the value is well above the threshold for opportunistic infections, viral suppression is sustained, and the clinical status is stable for more than 2 to 3 years. In patients with known or suspected complex drug resistance patterns, phenotypic resistance testing (usually in addition to genotypic resistance testing) should be performed (HHS [pediatric] 2017). Monitor for growth and development, signs of HIV-specific physical conditions, HIV disease progression, opportunistic infections, skin rash, or hypersensitivity.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Obtain liver function tests every 2 weeks for the first 4 weeks of therapy, then every 3 months thereafter. Also check liver function tests immediately if patient develops signs or symptoms consistent with hepatitis or hypersensitivity reactions and immediately in all patients who develop a rash within the first 18 weeks of therapy (HHS [pediatric] 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24957769\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma trough concentration &plusmn; standard deviation: 4,500 &plusmn; 1,900 ng/mL (HHS [pediatric] 2017)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200861\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As a non-nucleoside reverse transcriptase inhibitor, nevirapine has activity against HIV-1 by binding to reverse transcriptase. It consequently blocks the RNA-dependent and DNA-dependent DNA polymerase activities including HIV-1 replication. It does not require intracellular phosphorylation for antiviral activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200879\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and readily absorbed; Immediate release: &gt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely; V<sub>d</sub>: 1.2 L/kg; CSF penetration approximates 40% to 50% of plasma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: ~60%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via CYP3A4 and CYP2B6 (hydroxylation to inactive compounds); may undergo enterohepatic recycling; nevirapine is more rapidly metabolized in pediatric patients than in adults </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 93% (immediate release tablet); ~75% (extended release tablet [relative to immediate release]); 91% (oral solution) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Decreases over 2- to 4-week time with chronic dosing due to autoinduction (ie, half-life = 45 hours initially [single dose] and decreases to 25 to 30 hours [multiple dosing])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Immediate release: 4 hours; Extended release:~24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~81%, primarily as metabolites, &lt;3% as unchanged drug); feces (~10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Women have a 13.8% lower clearance compared to men; body size does not totally explain the gender difference</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200883\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Viramune Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (240 mL): $222.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Nevirapine ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (90): $718.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (30): $706.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Viramune XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (90): $951.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (30): $951.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Nevirapine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $650.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Viramune Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $1,025.69</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200886\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ciplanevimune (CO);</li>\n      <li>Hirapine (MY);</li>\n      <li>Nerapin (PY);</li>\n      <li>Neravir (TH);</li>\n      <li>Nevimat (ZW);</li>\n      <li>Nevimune (ET, IN, LK, ZW);</li>\n      <li>Nevimuno (PY);</li>\n      <li>Nevipan (ZW);</li>\n      <li>Nevira (BD);</li>\n      <li>Neviran (HR);</li>\n      <li>Nevitero (ZW);</li>\n      <li>Nevivir (ET);</li>\n      <li>Nuo Lan Pin (CN);</li>\n      <li>Viramune (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JO, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, SY, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);</li>\n      <li>Viramune XR (BB, HK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, Department of Health and Human Services. April 8, 2015. Available at <a href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. April 2017. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Updated March 27, 2017. Accessed July 17, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada (PHAC). Canadian guidelines on sexually transmitted infection. Available at http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php. Last modified December 2013. Accessed December 30, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viramune (nevirapine) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viramune XR (nevirapine) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; January 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12961 Version 215.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709170\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F200898\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F200899\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054342\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443899\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054335\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F200874\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F200858\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874746\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054346\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132873\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F3099313\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054345\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F200943\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F200941\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F200880\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F200862\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26018389\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F200929\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F200867\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F200884\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054341\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F24957769\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F200861\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F200879\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F200883\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F200886\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12961|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">Nevirapine: Drug information</a></li><li><a href=\"topic.htm?path=nevirapine-patient-drug-information\" class=\"drug drug_patient\">Nevirapine: Patient drug information</a></li></ul></div></div>","javascript":null}